OBJECTIVE: Smoking is highly intractable, and the genetic influences on cessation are unclear. Identifying the genetic factors affecting smoking cessation could elucidate the nature of tobacco dependence, enhance risk assessment, and support development of treatment algorithms. This study tested whether variants in the nicotinic receptor gene cluster CHRNA5-CHRNA3-CHRNB4 predict age at smoking cessation and relapse after an attempt to quit smoking. METHOD: In a community-based, crosssectional study (N=5,216) and a randomized comparative effectiveness smoking cessation trial (N=1,073), the authors used Cox proportional hazard models and logistic regression to model the relationships of smoking cessation (self-reported quit age in the community study and point-prevalence abstinence at the end of treatment in the clinical trial) to three common haplotypes in the CHRNA5-CHRNA3-CHRNB4 region defined by rs16969968 and rs680244. RESULTS: The genetic variants in the CHRNA5-CHRNA3-CHRNB4 region that predict nicotine dependence also predicted a later age at smoking cessation in the community sample. In the smoking cessation trial, haplotype predicted abstinence at end of treatment in individuals receiving placebo but not among individuals receiving active medication. Haplotype interacted with treatment in affecting cessation success. CONCLUSIONS:Smokers with the high-risk haplotype were three times as likely to respond to pharmacologic cessation treatments as were smokers with the low-risk haplotype. The high-risk haplotype increased the risk of cessation failure, and this increased risk was ameliorated by cessation pharmacotherapy. By identifying a high-risk genetic group with heightened response to smoking cessation pharmacotherapy, this work may support the development of personalized cessation treatments.
RCT Entities:
OBJECTIVE: Smoking is highly intractable, and the genetic influences on cessation are unclear. Identifying the genetic factors affecting smoking cessation could elucidate the nature of tobacco dependence, enhance risk assessment, and support development of treatment algorithms. This study tested whether variants in the nicotinic receptor gene cluster CHRNA5-CHRNA3-CHRNB4 predict age at smoking cessation and relapse after an attempt to quit smoking. METHOD: In a community-based, crosssectional study (N=5,216) and a randomized comparative effectiveness smoking cessation trial (N=1,073), the authors used Cox proportional hazard models and logistic regression to model the relationships of smoking cessation (self-reported quit age in the community study and point-prevalence abstinence at the end of treatment in the clinical trial) to three common haplotypes in the CHRNA5-CHRNA3-CHRNB4 region defined by rs16969968 and rs680244. RESULTS: The genetic variants in the CHRNA5-CHRNA3-CHRNB4 region that predict nicotine dependence also predicted a later age at smoking cessation in the community sample. In the smoking cessation trial, haplotype predicted abstinence at end of treatment in individuals receiving placebo but not among individuals receiving active medication. Haplotype interacted with treatment in affecting cessation success. CONCLUSIONS: Smokers with the high-risk haplotype were three times as likely to respond to pharmacologic cessation treatments as were smokers with the low-risk haplotype. The high-risk haplotype increased the risk of cessation failure, and this increased risk was ameliorated by cessation pharmacotherapy. By identifying a high-risk genetic group with heightened response to smoking cessation pharmacotherapy, this work may support the development of personalized cessation treatments.
Authors: Lutz P Breitling; Dorothee Twardella; Michael M Hoffmann; Stephanie H Witt; Jens Treutlein; Hermann Brenner Journal: Pharmacogenomics Date: 2010-04 Impact factor: 2.533
Authors: Wade H Berrettini; E Paul Wileyto; Leonard Epstein; Stephanie Restine; Larry Hawk; Peter Shields; Ray Niaura; Caryn Lerman Journal: Biol Psychiatry Date: 2006-07-28 Impact factor: 13.382
Authors: Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-01-25 Impact factor: 3.568
Authors: G Howard; L E Wagenknecht; G L Burke; A Diez-Roux; G W Evans; P McGovern; F J Nieto; G S Tell Journal: JAMA Date: 1998-01-14 Impact factor: 56.272
Authors: Nancy L Saccone; Robert C Culverhouse; Tae-Hwi Schwantes-An; Dale S Cannon; Xiangning Chen; Sven Cichon; Ina Giegling; Shizhong Han; Younghun Han; Kaisu Keskitalo-Vuokko; Xiangyang Kong; Maria Teresa Landi; Jennie Z Ma; Susan E Short; Sarah H Stephens; Victoria L Stevens; Lingwei Sun; Yufei Wang; Angela S Wenzlaff; Steven H Aggen; Naomi Breslau; Peter Broderick; Nilanjan Chatterjee; Jingchun Chen; Andrew C Heath; Markku Heliövaara; Nicole R Hoft; David J Hunter; Majken K Jensen; Nicholas G Martin; Grant W Montgomery; Tianhua Niu; Thomas J Payne; Leena Peltonen; Michele L Pergadia; John P Rice; Richard Sherva; Margaret R Spitz; Juzhong Sun; Jen C Wang; Robert B Weiss; William Wheeler; Stephanie H Witt; Bao-Zhu Yang; Neil E Caporaso; Marissa A Ehringer; Tim Eisen; Susan M Gapstur; Joel Gelernter; Richard Houlston; Jaakko Kaprio; Kenneth S Kendler; Peter Kraft; Mark F Leppert; Ming D Li; Pamela A F Madden; Markus M Nöthen; Sreekumar Pillai; Marcella Rietschel; Dan Rujescu; Ann Schwartz; Christopher I Amos; Laura J Bierut Journal: PLoS Genet Date: 2010-08-05 Impact factor: 5.917
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker Journal: Arch Gen Psychiatry Date: 2009-11
Authors: Timothy B Baker; Megan E Piper; Danielle E McCarthy; Daniel M Bolt; Stevens S Smith; Su-Young Kim; Suzanne Colby; David Conti; Gary A Giovino; Dorothy Hatsukami; Andrew Hyland; Suchitra Krishnan-Sarin; Raymond Niaura; Kenneth A Perkins; Benjamin A Toll Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: Chirag J Patel; Jacqueline Kerr; Duncan C Thomas; Bhramar Mukherjee; Beate Ritz; Nilanjan Chatterjee; Marta Jankowska; Juliette Madan; Margaret R Karagas; Kimberly A McAllister; Leah E Mechanic; M Daniele Fallin; Christine Ladd-Acosta; Ian A Blair; Susan L Teitelbaum; Christopher I Amos Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-07-14 Impact factor: 4.254
Authors: Henry R Kranzler; Rachel V Smith; Robert Schnoll; Afaf Moustafa; Emma Greenstreet-Akman Journal: Addiction Date: 2017-04-21 Impact factor: 6.526
Authors: K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur Journal: Clin Pharmacol Ther Date: 2013-03-18 Impact factor: 6.875
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Pharmacogenet Genomics Date: 2013-02 Impact factor: 2.089